Obesity Connect
Profile Image
Add Media
  • Saved

15h

Did you know?

While GLP-1 receptor agonists have established efficacy in obesity, dual agonism of both GIP and GLP-1 receptors has demonstrated superior weight loss in Phase 3 trials. The SURMOUNT-1 trial (n=2,539 adults with obesity without diabetes) found that the highest approved dose of tirzepatide achieved a mean body weight reduction of 22.5% from baseline over 72 weeks, compared to 2.4% with placebo (p<0.001) — the largest weight loss effect observed in any pharmacological obesity trial to date, approaching surgical outcomes.

NCCN Guidelines
Discussion question

As dual GIP/GLP-1 agonism achieves weight loss that approaches bariatric surgery outcomes, how is this changing your treatment algorithm for severe obesity — and how are you addressing the anticipated long-term therapy duration needed to maintain weight loss?

Profile Image
  • Uploads
  • 15h
    I am using this regularly in my practice, tirzepatide more than semaglutide when well tolerated. Cost barriers are still the most prohibitive factor, but once we get to a point Show More
  • 2w
    I use both Wegovy and Zepbound for chronic weight management . Wegovy is easier to get approved through insurance as compared to Zepbound unless patient has sleep apnea. Even after Show More

Show More Comments

  • Saved

2d
Clinical inertia in cardiovascular risk management: prevalence, associated factors, and impact on outcomes of the OPM study. - PubMed

Clinical inertia in cardiovascular risk management: prevalence, associated factors, and impact on outcomes of the OPM study. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42726073

Clinical inertia is prevalent in managing cardiovascular risk in primary care, leading to smaller reductions in cholesterol levels, but not affecting glycaemic parameters or triglycerides.


Clinical inertia affects over half of high-risk patients with uncontrolled hypertension, diabetes, or dyslipidaemia, leading to smaller reductions in total and LDL cholesterol.

Profile Image
  • Uploads
  • Saved

2d

Did you know? Obesity is a chronic, relapsing neurobiological disease driven by dysregulation of appetite-regulating hormones and energy homeostasis. GLP-1 receptor agonism reduces caloric intake centrally and slows gastric emptying. In the STEP 1 trial, once-weekly semaglutide achieved sustained weight reductions with many patients losing more than 15% of body weight, along with meaningful improvements in cardiometabolic risk factors.

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

NCCN Guidelines

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

Profile Image
  • Uploads
  • 2d
    Framing obesity as a chronic disease takes the onus of causality somewhat off the patient's shoulders. It also reinforces the need for lifelong lifestyle changes. This enhances the Show More
  • 6d
    I APPROACH OBESITY AS A CHRONIC , METABOLIC CONDITION JUST LIKE DIABETES AND HYPERTENSION AND OFFER MEDICATIONS TO COMBAT THIS DISEASE ALONG WITH LIFESTYLE MODIFICATIONS.

Show More Comments

  • Saved

4d
Background Image DesktopBackground Image Mobile

Obesity is increasingly recognized as a chronic inflammatory condition associated with altered metabolic signaling, insulin resistance, and systemic health complications. Growing evidence supports the importance of early, sustained approaches to long-term weight management.

See how obesity affects whole-body health

Profile Image
  • Uploads
  • 4d
    obesity is a large issue because we know that it affects so many system functions and has an overall poor contribution to major disorders i.e. diabetes, htn, arthritis, dementia, cva Show More
  • 4w
    A very complicated disease with protean manifestations. The #1 killer in the US.

Show More Comments

  • Saved

1w
The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. - PubMed

The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42699752

Explore the metabolic risks of obesity in Malaysia and the need for coordinated policy efforts. Examine key obesity management strategies despite existing frameworks.


Metabolic risk starts below BMI 23 kg/m, with waist-to-height ratio >0.5 as an unhealthy threshold. Descriptive epidemiology dominates, with scarce longitudinal and experimental studies.

Profile Image
  • Uploads